Diabetic kidney disease as a combination-therapy story
SGLT2 plus finerenone plus GLP-1 stacking in diabetic kidney disease is generating the first real combination-therapy outcomes data.
Diabetic kidney disease has historically been single-mechanism therapy. Trial-level and real-world data on the combination of SGLT2 inhibitors, finerenone, and GLP-1 agents is now characterising the additive benefit. The implementation question is whether nephrology or diabetology owns the multi-mechanism prescribing.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is heart failure?
- SnapshotHFrEF therapy reference (2026)
- ExplainedWhat is ATTR cardiomyopathy?
TreatmentReal world evidencePatient journey
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.